Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9FPU

Crystal structure of carbonic anhydrase II with N-butyl-4-chloro-3-sulfamoyl-benzamide

This is a non-PDB format compatible entry.
Summary for 9FPU
Entry DOI10.2210/pdb9fpu/pdb
DescriptorCarbonic anhydrase 2, ZINC ION, ~{N}-butyl-4-chloranyl-3-sulfamoyl-benzamide, ... (7 entities in total)
Functional Keywordsdrug design, carbonic anhydrase, benzenesulfonamide, lyase-lyase inhibitor complex, lyase
Biological sourceHomo sapiens (human)
Total number of polymer chains1
Total formula weight29909.53
Authors
Smirnov, A.,Manakova, E.N.,Grazulis, S.,Paketuryte, V. (deposition date: 2024-06-13, release date: 2025-06-25, Last modification date: 2025-10-08)
Primary citationZaksauskas, A.,Paketuryte-Latve, V.,Jankunaite, A.,Capkauskaite, E.,Becart, Y.,Smirnov, A.,Pospisilova, K.,Leitans, J.,Brynda, J.,Kazaks, A.,Baranauskiene, L.,Manakova, E.,Grazulis, S.,Kairys, V.,Tars, K.,Rezacova, P.,Matulis, D.
Affinity and Selectivity of Protein-Ligand Recognition: A Minor Chemical Modification Changes Carbonic Anhydrase Binding Profile.
J.Med.Chem., 68:17752-17773, 2025
Cited by
PubMed Abstract: Discovery of small-molecule drugs relies on their strong binding affinity compared to nontarget proteins, thus possessing selectivity. Minor chemical structure changes usually exhibit little change in the compound efficacy, with rare exceptions. We developed a series of nearly 50 -substituted benzenesulfonamides and experimentally measured their interactions with the 12 catalytically active human carbonic anhydrase (CA) isozymes. Inhibitors were designed using seven different substituent groups, including 4--substituted 3-sulfamoyl benzoates and benzamides, 4--substituted 3-sulfamoyl benzoates and benzamides, 4--substituted 3-sulfamoyl benzoates and benzamides, and 4-amino-substituted benzamides. The oxidation state of sulfur at the position significantly influenced the compound's affinity for CAIX, a target for anticancer drugs, demonstrating affinities hundreds of thousands of times stronger than related compounds. Coupled with X-ray crystal structures and molecular docking, the relationship between structure and thermodynamics offers insights into how small changes in the structure lead to significant changes in affinity for drug design.
PubMed: 40801814
DOI: 10.1021/acs.jmedchem.5c01421
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.12 Å)
Structure validation

243083

数据于2025-10-15公开中

PDB statisticsPDBj update infoContact PDBjnumon